rabeprazole has been researched along with Rhabdomyolysis in 1 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
Excerpt | Relevance | Reference |
---|---|---|
"Polymyositis occurring in patients treated with omeprazole has been signalled as a possible adverse drug reaction (ADR) by the New Zealand Intensive Medicines Monitoring Programme (IMMP) and the WHO Collaborating Centre for International Drug Monitoring: the Uppsala Monitoring Centre (UMC)." | 4.83 | Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? ( Clark, DW; Strandell, J, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Clark, DW | 1 |
Strandell, J | 1 |
1 review available for rabeprazole and Rhabdomyolysis
Article | Year |
---|---|
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; | 2006 |